Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reiterated by research analysts at Wells Fargo & Co in a research note issued on Tuesday.

Several other research analysts have also recently issued reports on VRX. HC Wainwright increased their price target on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald reissued a “buy” rating and set a $23.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, September 28th. Zacks Investment Research cut shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a report on Saturday, January 13th. Vetr raised shares of Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 target price for the company in a report on Thursday, September 28th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $16.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, October 3rd. Six equities research analysts have rated the stock with a sell rating, nine have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has a consensus rating of “Hold” and an average target price of $18.56.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at $22.70 on Tuesday. The stock has a market cap of $7,910.00, a PE ratio of 5.82, a P/E/G ratio of 0.73 and a beta of -0.22. Valeant Pharmaceuticals Intl has a 1-year low of $8.31 and a 1-year high of $24.43. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a net margin of 15.35% and a return on equity of 51.56%. analysts predict that Valeant Pharmaceuticals Intl will post 3.82 EPS for the current fiscal year.

In other Valeant Pharmaceuticals Intl news, Director John Paulson acquired 344,216 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was acquired at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.87% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Eaton Vance Management increased its stake in shares of Valeant Pharmaceuticals Intl by 1.2% during the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 500 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Valeant Pharmaceuticals Intl by 1.7% during the 2nd quarter. Nationwide Fund Advisors now owns 52,400 shares of the specialty pharmaceutical company’s stock worth $907,000 after purchasing an additional 900 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Valeant Pharmaceuticals Intl by 10.5% during the 2nd quarter. GSA Capital Partners LLP now owns 21,651 shares of the specialty pharmaceutical company’s stock worth $375,000 after purchasing an additional 2,051 shares in the last quarter. Moors & Cabot Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 32.3% during the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after purchasing an additional 3,725 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 4,512 shares in the last quarter. 49.45% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl (VRX) Receives “Sell” Rating from Wells Fargo & Co” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/18/valeant-pharmaceuticals-intl-vrx-receives-sell-rating-from-wells-fargo-co.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.